BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26167079)

  • 1. Clinical predictors of thiopurine-related adverse events in Crohn's disease.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Eksteen B; Ghosh S; Panaccione R
    World J Gastroenterol; 2015 Jul; 21(25):7795-804. PubMed ID: 26167079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine-induced pancreatitis in inflammatory bowel diseases.
    Ledder O; Lemberg DA; Day AS
    Expert Rev Gastroenterol Hepatol; 2015 Apr; 9(4):399-403. PubMed ID: 25494551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
    Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
    Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
    Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
    Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
    González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
    J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
    Chaparro M; Ordás I; Cabré E; Garcia-Sanchez V; Bastida G; Peñalva M; Gomollón F; García-Planella E; Merino O; Gutiérrez A; Esteve M; Márquez L; Garcia-Sepulcre M; Hinojosa J; Vera I; Muñoz F; Mendoza JL; Cabriada JL; Montoro MA; Barreiro-de Acosta M; Ceña G; Saro C; Aldeguer X; Barrio J; Maté J; Gisbert JP
    Inflamm Bowel Dis; 2013 Jun; 19(7):1404-10. PubMed ID: 23665964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE; Kamm MA; Hartono JL; Lust M
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
    López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
    Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Mercaptopurine for Azathioprine Intolerant Inflammatory Bowel Disease: Literature Search and Reappraisal of Own Data.
    Actis GC; Pellicano R; Rosina F
    Inflamm Allergy Drug Targets; 2015; 14(2):133-7. PubMed ID: 26728773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
    Akiyama S; Matsuoka K; Fukuda K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Motobayashi M; Suzuki K; Takenaka K; Fujii T; Saito E; Nagahori M; Ohtsuka K; Mochizuki M; Watanabe M; Hashiguchi M; Kanai T
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1751-1757. PubMed ID: 31045285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.